Portal de investigación
Anti-inflammatory effects and improved metabolic derangements in ob/ob mice by a newly synthesized prenylated benzopyran with pan-PPAR activity
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Collado, Aida
- Duplan, Isabelle
- Hennuyer, Nathalie
- Garibotto, Francisco
- Enriz, Ricardo D
- Dacquet, Catherine
- Staels, Bart
Grupos y Plataformas de I+D+i
Abstract
Background and purpose: Selective peroxisome proliferator-activated receptors (PPARs) are widely used to treat metabolic complications; however, the limited effect of PPAR alpha agonists on glucose metabolism and the adverse effects associated with selective PPAR gamma activators have stimulated the development of novel pan-PPAR agonists to treat metabolic disorders. Here, we synthesized a new prenylated benzopyran (BP-2) and evaluated its PPAR-activating properties, anti-inflammatory effects and impact on metabolic derangements. Experimental approach: BP-2 was used in transactivation assays to evaluate its agonism to PPAR alpha, PPAR beta/delta and PPAR gamma. A parallel-plate flow chamber was employed to investigate its effect on TNF alpha-induced leukocyteendothelium interactions. Flow cytometry and immunofluorescence were used to determine its effects on the expression of endothelial cell adhesion molecules (CAMs) and chemokines and p38-MAPK/NF-kappa B activation. PPARs/RXR alpha interactions were determined using a gene silencing approach. Analysis of its impact on metabolic abnormalities and inflammation was performed in ob/ob mice. Key results: BP-2 displayed strong PPAR alpha activity, with moderate and weak activity against PPAR beta/delta and PPAR gamma, respectively. In vitro, BP-2 reduced TNF alpha-induced endothelial ICAM-1, VCAM-1 and fractalkine/CX3CL1 expression, suppressed mononuclear cell arrest via PPAR beta/delta-RXR alpha interactions and decreased p38-MAPK/NF-kappa B activation. In vivo, BP-2 improved the circulating levels of glucose and triglycerides in ob/ob mice, suppressed Tlymphocyte/macrophage infiltration and proinflammatory markers in the liver and white adipose tissue, but increased the expression of the M2-like macrophage marker CD206.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1043-6618, 1096-1186
- Tipo:
- Article
- Páginas:
- 106638-106638
- PubMed:
- 36586645
PHARMACOLOGICAL RESEARCH Elsevier Inc.
Citas Recibidas en Web of Science: 13
Documentos
Filiaciones
Keywords
- Prenylated benzopyran; PPAR; Molecular modeling; Metabolic disorders; Anti-inflammatory effects; ob/ob mice
Financiación
Proyectos y Estudios Clínicos
Synthesis and pharmacological evaluation of new dual PPARalpha/gamma agonists as new therapeutic tools in the control of cardiometabolic disorders
Investigador Principal: NURIA CABEDO ESCRIG
CP15/00150 . INSTITUTO SALUD CARLOS III . 2016
RETOS 2017. MODULACION FARMACOLOGICA DEL SISTEMA INMUNE COMO DIANA CLAVE EN LA PREVENCION DE LA ENFERMEDAD CARDIOVASCULAR ASOCIADA A DESORDENES METABOLICOS. SINTESIS DE FARMACOS NOVEDOSOS
Investigador Principal: MARIA JESUS SANZ FERRANDO
SAF2017-89714-R . MINISTERIO ECONOMIA Y COMPETITIVIDAD . 2018
Identificación de nuevos mecanismos implicados en la angiogénesis e inflamación en pacientes obesos. Modulación por ligandos de receptores nucleares constitutivos de androstano.
Investigador Principal: JOSE TOMAS REAL COLLADO
PI18/00209 . INSTITUTO SALUD CARLOS III . 2019
Desarrollo quimico y farmacologico de nuevos farmacos "multidiana" en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular asociada
Investigador Principal: NURIA CABEDO ESCRIG
PI18/01450 . INSTITUTO SALUD CARLOS III . 2019
Efecto de la cirugía bariátrica en la inflamación vascular en pacientes con obesidad morbida y diabéticos.
Investigador Principal: LAURA PIQUERAS RUIZ
AICO/2019/250 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO . 2019
Desarrollo de nuevos fármacos “multidiana” en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular associada.
Investigador Principal: NURIA CABEDO ESCRIG
APOTIP/2020/011 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO
CONTRATOS MIGUEL SERVET TIPO II
Investigador Principal: NURIA CABEDO ESCRIG
CPII20/00010 . INSTITUTO SALUD CARLOS III
Desarrollo de nuevos moduladores multidiana de receptores nucleares y biomarcadores lipídicos para el tratamiento del síndrome metabólico y las comorbilidades asociadas.
Investigador Principal: NURIA CABEDO ESCRIG
PI21/02045 . INSTITUTO SALUD CARLOS III . 2022
Cita
Marques P,Villarroel C,Collado A,Garcia A,Vila L,Duplan I,Hennuyer N,Garibotto F,Enriz RD,Dacquet C,Staels B,Piqueras L,Cortes D,Sanz M,Cabedo N. Anti-inflammatory effects and improved metabolic derangements in <i>ob</i>/<i>ob</i> mice by a newly synthesized prenylated benzopyran with pan-PPAR activity. Pharmacol. Res. 2023. 187. p. 106638-106638. IF:9,100. (1).
Anti-inflammatory effects and improved metabolic derangements in <i>ob</i>/<i>ob</i> mice by a newly synthesized prenylated benzopyran with pan-PPAR activity. Marques P, Villarroel C, Collado A, Garcia A, Vila L, Duplan I, Hennuyer N et al. PHARMACOLOGICAL RESEARCH. 2023 enero 01. 187106638-106638. DOI:10.1016/j.phrs.2022.106638. PMID:36586645.
